Healthcare Stocks See Bullish Sentiments from Analysts

Analysts at Bloomberg offer bullish sentiments on Agilent (A), Ascendis Pharma (ASND), and Kalaris Therapeutics (KLRS). Puneet Souda of Leerink Partners maintains a Buy rating on Agilent with a $137.62 price target, while Jessica Fye of J.P. Morgan maintains a Buy rating on Ascendis Pharma with a $245.00 price target. Lachlan Hanbury Brown of William Blair maintains a Buy rating on Kalaris Therapeutics.

Analysts at Bloomberg have expressed bullish sentiments on Agilent Technologies Inc. (A), Ascendis Pharma A/S (ASND), and Kalaris Therapeutics Inc. (KLRS), with several prominent firms maintaining Buy ratings and setting optimistic price targets.

Puneet Souda of Leerink Partners maintains a Buy rating on Agilent with a $137.62 price target [1]. Jessica Fye of J.P. Morgan maintains a Buy rating on Ascendis Pharma with a $245.00 price target [2]. Lachlan Hanbury Brown of William Blair maintains a Buy rating on Kalaris Therapeutics [3].

These analysts' positive views are based on the companies' strong fundamentals, promising pipelines, and potential for growth. Agilent, a provider of life science and chemical analysis solutions, has shown resilience in the face of market challenges and is expected to benefit from ongoing advancements in biotechnology and diagnostics. Ascendis Pharma, a biopharmaceutical company, has a robust pipeline of therapies for unmet medical needs, including growth hormone deficiency and rare diseases. Kalaris Therapeutics, a biotechnology company focused on cancer immunotherapies, has shown promising results in its clinical trials.

Investors should consider the potential risks and rewards associated with these companies before making investment decisions. While the analysts' ratings and price targets provide valuable insights, they should be used as part of a broader analysis, including an assessment of each company's financial health, competitive position, and market outlook.

References:
[1] https://www.marketbeat.com/instant-alerts/filing-ascendis-pharma-as-nasdaqasnd-position-decreased-by-crossmark-global-holdings-inc-2025-07-12/
[2] https://www.nasdaq.com/articles/wall-street-analysts-believe-ascendis-pharma-asnd-could-rally-2983-heres-how-trade
[3] https://www.bloomberg.com/news/articles/2025-07-02/analysts-offer-bullish-sentiments-on-agilent-ascendis-pharma-and-kalaris-therapeutics